article Open AccessTop 10% cited

Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis

Lara D. Veeken · 2005 · Vol. 45(1) · pp. 50–52

David R. Blake✉(Royal National Hospital for Rheumatic Diseases)Philip Robson(Oxford Research (Norway))Madeline Ho(Northampton General Hospital)R. W. Jubb(Selly Oak Hospital)Candy McCabe(Royal National Hospital for Rheumatic Diseases)

View via DOI Full-text PDF

Abstract

In the first ever controlled trial of a CBM in RA, a significant analgesic effect was observed and disease activity was significantly suppressed following Sativex treatment. Whilst the differences are small and variable across the population, they represent benefits of clinical relevance and show the need for more detailed investigation in this indication.

Cannabis and Cannabinoid Research Toxin Mechanisms and Immunotoxins Respiratory and Cough-Related ResearchMedicineTolerabilityRheumatoid arthritisAlternative medicinePhysical therapyAdverse effectInternal medicinePathology

MeSH terms

Administration, OralAnalgesicsArthritis, RheumatoidCannabidiolDouble-Blind MethodDrug CombinationsFemaleHumansMaleMiddle AgedPainPain MeasurementPlant ExtractsDronabinolTreatment Outcome